RNA, U4 small nuclear 86, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-86P profile across patient tissues and cancer cell-line models. RNU4-86P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU4-86P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, RNU4-86P RNA expression shows 6,013 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where RNU4-86P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-86P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-86P survival associations across molecular data types. RNU4-86P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-86P RNA expression–survival associations across cancer types. High RNU4-86P expression shows unfavorable associations in HNSC, SKCM, KIRC and THCA, but favorable associations in STAD and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU4-86P RNA expression.
This table summarizes RNU4-86P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-86P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-86P shows lower tumor expression in THCA and STAD and higher tumor expression in HNSC, CHOL and BRCA. The HNSC box plot shows higher RNU4-86P RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .011).
This table shows molecular features associated with RNU4-86P in patient tissues and cancer cell lines. In patient samples, RNU4-86P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
